Preparation of Hybrid Strain of Human-Mouse Cell Fusion Maternal-Fetal Blood Group Incompatibility Therapy

Abstract

A person who is used in the field of medicine-Preparation of mouse cell fusion maternal-fetal blood group incompatibility therapy hybrid strain, characterized by, Using erythropoietin as inducer, ''O'' type human bone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, Then the cultured human bone marrow cells were fused with murine myeloma cells to form hybridized cells, Erythropoietin was use to induce that directional differentiation of the hybridized cell, hybrid cell clones were screened by HAT. The hybridization strains of Rh positive cells which can be expanded indefinitely in vitro were screened by Rh antibody, As that adsorbent aft industrialized amplification. A low-cost and safe method for that treatment of maternal-fetal blood group incompatibility hemolytic disease without plasma exchange solution without remove plasma and its beneficial ingredients is create by absorbing pathogenic Rh antibody in peripheral plasmaof pregnant women with maternal-fetal blood group incompatibility through an in vitro adsorption device which is formed by an adsorber and a blood separator.

Description

technical field [0001] The invention relates to the preparation of hybrid strains for the treatment of maternal-fetal blood type incompatibility in the field of medicine, and is mainly used for adsorption and removal of anti-fetal red blood cell antibodies in plasma of pregnant women with maternal-fetal Rh blood type incompatibility. Background technique [0002] Humans have 26 blood types such as ABO, Rh, MN, Lew, and Kell, among which the most important are ABO blood type and Rh blood type. ABO blood type is divided into A according to the A antigen, B antigen, AB antigen or no A and B antigen carried by red blood cells Type B, Type AB and Type O; Rh blood type is divided into Rh positive and Rh negative according to whether the red blood cells carry D antigen. The frequency of Rh negative in the Han population in my country is about 0.4%, while the frequency of Rh negative in the minority nationalities in Northwest China and some countries is as high as 10%, so the incide...

AI Technical Summary

Problems solved by technology

Theoretically, this treatment method is obviously superior to the existing treatment methods, but the problem is that these literatures have not yet proposed an in vitro expansion method for Rh-positive "O" red blood cells, and the Rh-positive "O" type human used Red blood cells or rhesus monkey red blood cells can only be taken directly from Rh-positive humans or rhesus monkeys

The applicant also tried to find or trial-produce non-red blood cell materials capable of absorbing Rh antibodies, but so far failed

Images